Akebia Therapeutics, Inc. (FRA:AX9)
Germany · Delayed Price · Currency is EUR 1.184
+0.004 (0.34%)
At close: Jan 30, 2026
Akebia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 225.07 | 160.18 | 194.62 | 292.48 | 211.65 | 294.64 | |
Revenue Growth (YoY) | 32.49% | -17.70% | -33.46% | 38.19% | -28.17% | -12.05% |
Cost of Revenue | 37.55 | 26.15 | 39.76 | 22.5 | 81.49 | 63.96 |
Gross Profit | 187.53 | 134.03 | 154.86 | 269.99 | 130.16 | 230.68 |
Selling, General & Admin | 109.07 | 106.55 | 100.23 | 138.6 | 174.14 | 154.1 |
Research & Development | 47.5 | 37.65 | 63.08 | 129.99 | 147.85 | 218.49 |
Amortization of Goodwill & Intangibles | 9.01 | 36.04 | 36.04 | 36.04 | 36.04 | 32.62 |
Operating Expenses | 165.57 | 180.24 | 199.35 | 304.63 | 358.03 | 405.2 |
Operating Income | 21.95 | -46.21 | -44.5 | -34.64 | -227.88 | -174.52 |
Interest Expense | -26.23 | -18.19 | -6.03 | -15.69 | -20.02 | -8.92 |
Interest & Investment Income | - | - | - | - | 0.07 | - |
Other Non Operating Income (Expenses) | -6.81 | -0.24 | 0.89 | 3.15 | 2.41 | 1.86 |
EBT Excluding Unusual Items | -11.08 | -64.63 | -49.64 | -47.18 | -245.42 | -181.58 |
Merger & Restructuring Charges | - | -0.06 | -0.18 | -15.93 | -21.58 | -68.24 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.02 | 0.05 |
Asset Writedown | -4.21 | -4.21 | -1.58 | -30.24 | -15.05 | -135.07 |
Other Unusual Items | - | -0.52 | -0.52 | -0.87 | - | - |
Pretax Income | -15.29 | -69.41 | -51.93 | -94.23 | -282.02 | -384.84 |
Income Tax Expense | 0.62 | - | - | - | - | - |
Net Income | -15.91 | -69.41 | -51.93 | -94.23 | -282.02 | -384.84 |
Net Income to Common | -15.91 | -69.41 | -51.93 | -94.23 | -282.02 | -384.84 |
Shares Outstanding (Basic) | 245 | 211 | 187 | 183 | 166 | 138 |
Shares Outstanding (Diluted) | 245 | 211 | 187 | 183 | 166 | 138 |
Shares Change (YoY) | 20.49% | 12.53% | 2.56% | 10.14% | 19.85% | 16.95% |
EPS (Basic) | -0.06 | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 |
EPS (Diluted) | -0.06 | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 |
Free Cash Flow | 32.17 | -40.69 | -23.38 | -73.27 | -253.02 | -110.71 |
Free Cash Flow Per Share | 0.13 | -0.19 | -0.13 | -0.40 | -1.52 | -0.80 |
Gross Margin | 83.32% | 83.68% | 79.57% | 92.31% | 61.50% | 78.29% |
Operating Margin | 9.75% | -28.85% | -22.86% | -11.84% | -107.67% | -59.23% |
Profit Margin | -7.07% | -43.33% | -26.68% | -32.22% | -133.25% | -130.61% |
Free Cash Flow Margin | 14.29% | -25.40% | -12.02% | -25.05% | -119.55% | -37.57% |
EBITDA | 32.25 | -8.7 | -6.87 | 3.06 | -189.91 | -139.83 |
EBITDA Margin | 14.33% | -5.43% | -3.53% | 1.04% | -89.73% | -47.46% |
D&A For EBITDA | 10.29 | 37.5 | 37.63 | 37.7 | 37.97 | 34.69 |
EBIT | 21.95 | -46.21 | -44.5 | -34.64 | -227.88 | -174.52 |
EBIT Margin | 9.75% | -28.85% | -22.86% | -11.84% | -107.67% | -59.23% |
Revenue as Reported | 225.07 | 160.18 | 194.62 | 292.48 | 211.65 | 294.64 |
Advertising Expenses | - | 4.6 | 1 | 6.7 | 8.2 | 5 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.